Ready, folks here are expecting that it will be a non-issue and that NW Bio will release news of magnitude before the next capital raise is upon us. Surely they wouldn't spend on initiating Direct if they thought money would be an issue. Also hopefully a halt means that expenses have gone down considerably on the Phase III. I can't imagine they're paying $250k a month to clinical sites during a halt. Anyway time will tell.
Market Data 
Markets 
AI
